One of the keys to decreasing the incidence of active tuberculosis (TB) is preventing reactivation by aggressively treating latent TB infection. The American Thoracic Society and the CDC endorse 2 regimens using isoniazid (INH) and 1 regimen using rifampin. A 9-month regimen of INH is optimal for most patients. However, the drug is associated with mild hepatotoxicity and hepatitis. If aminotransferase levels are 3 to 5 times higher than normal or the patient has signs and symptoms such as nausea, vomiting, anorexia, persistently dark urine, jaundice, malaise, unexplained fever for more than 3 days, or right upper quadrant tenderness, INH should be discontinued. A daily dose of rifampin (600 mg in adults and 10 to 20 mg/kg in children) is reserved for persons exposed to patients with INH-resistant and rifampin-sensitive disease.
|Original language||English (US)|
|Number of pages||8|
|Journal||Journal of Respiratory Diseases|
|State||Published - Nov 2004|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine